PharmaBlock Sciences Nanjing Inc Class A - Asset Resilience Ratio
PharmaBlock Sciences Nanjing Inc Class A (300725) has an Asset Resilience Ratio of 10.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PharmaBlock Sciences Nanjing Inc Class A working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how PharmaBlock Sciences Nanjing Inc Class A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PharmaBlock Sciences Nanjing Inc Class A (300725) total assets.
Liquid Assets Composition Over Time
This chart breaks down PharmaBlock Sciences Nanjing Inc Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read PharmaBlock Sciences Nanjing Inc Class A total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥687.58 Million | 10.76% |
| Total Liquid Assets | CN¥687.58 Million | 10.76% |
Asset Resilience Insights
- Moderate Liquidity: PharmaBlock Sciences Nanjing Inc Class A has 10.76% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
PharmaBlock Sciences Nanjing Inc Class A Industry Peers by Asset Resilience Ratio
Compare PharmaBlock Sciences Nanjing Inc Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for PharmaBlock Sciences Nanjing Inc Class A (2014–2025)
The table below shows the annual Asset Resilience Ratio data for PharmaBlock Sciences Nanjing Inc Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.02% | CN¥735.57 Million ≈ $107.64 Million |
CN¥7.34 Billion ≈ $1.07 Billion |
+0.59pp |
| 2024-12-31 | 9.43% | CN¥465.61 Million ≈ $68.13 Million |
CN¥4.94 Billion ≈ $722.19 Million |
-11.91pp |
| 2023-12-31 | 21.35% | CN¥1.09 Billion ≈ $159.44 Million |
CN¥5.10 Billion ≈ $746.88 Million |
+17.99pp |
| 2022-12-31 | 3.36% | CN¥163.30 Million ≈ $23.90 Million |
CN¥4.86 Billion ≈ $711.49 Million |
-5.32pp |
| 2021-12-31 | 8.68% | CN¥304.43 Million ≈ $44.55 Million |
CN¥3.51 Billion ≈ $513.17 Million |
+4.24pp |
| 2020-12-31 | 4.44% | CN¥107.62 Million ≈ $15.75 Million |
CN¥2.43 Billion ≈ $354.90 Million |
+2.35pp |
| 2019-12-31 | 2.09% | CN¥21.52 Million ≈ $3.15 Million |
CN¥1.03 Billion ≈ $150.60 Million |
+0.12pp |
| 2014-12-31 | 1.97% | CN¥2.00 Million ≈ $292.66K |
CN¥101.56 Million ≈ $14.86 Million |
-- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the di… Read more